They seem to be selling hope rather than actually trying sincerely to do the work necessary to get FDA approval.
The clinical study they base their whole show on, is too small to take seriously.
They spend more on admin and employee stock grants than R&D.
I sold out my position a few months back.
Recent CLVSQ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/18/2023 04:15:24 AM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/11/2023 04:09:55 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/11/2023 04:05:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/11/2023 03:43:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 01:37:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 09:08:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM